Objective To investigate the therapeutic effect of immunomodulator combined with budesonide on chronic obstructive pulmonary disease(COPD) and its influence on airway mucus hypersecretion and prognosis.Methods From September 2019 to September 2021, 80 patients with COPD were selected from the Department of Respiratory and Critical Care Medicine of Sinopharm Tongmei General Hospital. They were randomly divided into control group and research group, with 40 patients in each group. The control group was treated with budesonide, while the study group was treated with budesonide plus immunomodulator. To compare the clinical efficacy of the two groups, pulmonary function indexes [forced expiratory volume in the first second/forced vital capacity(FEV₁/FVC), FEV₁% of the estimated value(FEV₁%), residual volume/total lung volume(RV/TLC)], Treg/Th17 cytokines [interleukin-17(IL-17), transforming growth factor) before and after treatment-β₁(TGF-β₁), IL-10], airway mucus hypersecretion related indicators [Toll like receptor 4(TLR4), mucin 5AC(MUC5ac), dry/wet proportion of sputum], adverse reactions and prognosis.Results After 4 weeks of treatment, the total effective rate of the study group was higher than that of the control group(95.00% vs.65.00%,χ²=11.250,P=0.001). FEV₁/FVC, FEV₁% in the study group were higher than those in the control group(t/P=2.498/0.015, 3.177/0.002), and RV/TLC were lower than those in the control group(t=4.557, P<0.001). Study group sputum IL-10, TGF-β₁. TLR4 was higher than that in the control group(t=4.514, 9.407, 3.575, P<0.001). The dry/wet specific gravity of IL-17, MUC5ac and sputum in the control group was lower than that in the control group(t=6.232, 4.046, 8.771, P<0.001). there="" was="" no="" significant="" difference="" in="" the="" incidence="" of="" adverse="" reactions="" between="" two="" p="">0.05). Follow up after 12 weeks of treatment showed that the number of acute exacerbations in the study group was less than that in the control group(t=10.849, P<0.001), and the readmission rate was lower than that in the control group(χ²=4.451, P=0.034).Conclusion The combination of immunomodulator and budesonide in the treatment of COPD has a significant effect, which can alleviate the airway mucus hypersecretion, alleviate clinical symptoms, improve immune function, and further improve the prognosis.

Chronic obstructive pulmonary disease;                    Immunomodulators;                    Budegefo;                    Airway mucus hypersecretion;